Patients seeking Eli Lilly‘s weight loss medications Zepbound and Foundayo can now have their medications evaluated, prescribed and shipped directly through Hims & Hers under a new partnership between the two companies, Reuters reports.
Announced on Nov. 6, 2026, the agreement enables eligible patients to complete an online consultation, receive a prescription if medically necessary and have their medication delivered straight to their door without leaving the Hims & Hers website—eliminating the previous requirement to exit the platform and order through LillyDirect.
The deal also introduces self-pay starting prices of $149 a month for Foundayo and $299 a month for Zepbound. However, patients need to account for recurring membership fees and clinical eligibility requirements before signing up.
What does the Eli Lilly Hims & Hers partnership mean for weight loss drug access?
The collaboration brings a major pharmaceutical manufacturer together with a fast-growing digital health platform, creating a direct-to-patient pipeline for FDA-approved obesity treatments. Under the arrangement, customers complete a health questionnaire online and consult with a licensed healthcare professional through Hims & Hers, who can prescribe treatment for home delivery if clinically appropriate.
For Eli Lilly, removing friction from the sign-up process was a central driver behind the deal. In an interview with Reuters, Lilly USA president Ilya Yuffa explained that requiring users to navigate away from Hims & Hers to fulfill prescriptions on LillyDirect created unnecessary barriers.
“The ease and ability for someone on the Hims & Hers platform today to get Lilly medicine is not fully straightforward,” Yuffa said, noting that every additional step makes a patient more likely to drop out of the process.
The partnership also strengthens Eli Lilly’s competitive position against Novo Nordisk, which already offers its weight loss and diabetes drugs, Wegovy and Ozempic, through Hims & Hers. Bringing both Zepbound and Foundayo onto the platform gives injectable and oral options for patients who prefer virtual care over an initial in-person doctor’s visit.
Which Eli Lilly weight loss drugs will be available through Hims & Hers?
The agreement covers two FDA-approved obesity medications, giving eligible patients a choice between a weekly injection and a daily pill:
- Zepbound (tirzepatide): A once-weekly injection that stimulates two hormone receptors—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Activating both receptors helps regulate blood sugar, increase feelings of fullness and reduce appetite.
- Foundayo (orforglipron): A once-daily oral tablet and GLP-1 receptor agonist that targets the GLP-1 receptor to help control appetite and food intake.
Both medications are approved for adults with obesity, or adults who are overweight with at least one weight-related health condition, and are intended to be used alongside a reduced-calorie diet and regular physical activity.
Dr. Justus Rabach, MD, a primary care physician and Blavity Health medical reviewer, warns, “Not all the treatments are appropriate for everyone. Both medications, for instance, have a specific warning for potential thyroid C-cell tumors, and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.”
How much will Zepbound and Foundayo cost through Hims & Hers?
The partnership offers the following starting self-pay prices for the lowest doses:
- Foundayo: Starting at $149 per month
- Zepbound: Starting at $299 per month
Higher doses may cost more. While these medication prices match the self-pay rates available on LillyDirect and are designed for patients paying out of pocket rather than using insurance, they do not include the required Hims & Hers weight loss membership. Hims & Hers charges $39 for the first month and $149 per month thereafter, billed separately from the medication.
Before enrolling, patients should factor in the combined monthly cost:
- Foundayo total: $188 in the first month ($39 membership + $149 medication), rising to $298 or more per month from the second month onward ($149 membership + $149 or more medication).
- Zepbound total: $338 in the first month ($39 membership + $299 medication), rising to $448 or more per month from the second month onward ($149 membership + $299 or more medication).
Patients who already have a prescription from an independent doctor and purchase directly through LillyDirect avoid the $149 monthly Hims & Hers subscription, though they remain responsible for any separate clinic visit costs.
How will patients get prescriptions for Eli Lilly’s weight loss drugs through Hims & Hers?
To begin treatment through Hims & Hers, patients complete an online health screening form that is reviewed by a licensed healthcare provider. The provider evaluates the patient’s weight, medical history, underlying health conditions and current medications to determine whether Zepbound or Foundayo is medically appropriate.
Completing the intake form does not guarantee a prescription. Providers must weigh potential risks, contraindications and drug interactions before approving treatment.
According to Hims & Hers, its weight loss membership includes ongoing access to licensed providers, weight loss tracking, support for dosage adjustments and side effects, and personalized treatment planning. Even with those digital tools, patients should confirm who will oversee their long-term care, how often clinical follow-ups occur and where to seek urgent medical evaluation if serious side effects develop.
What does the partnership mean for compounded GLP-1 weight loss drugs?
The agreement also marks a shift in how pharmaceutical companies interact with telehealth platforms that previously relied on compounded weight-loss medications.
Compounded drugs are custom-mixed by pharmacists or qualified healthcare workers to meet individual patient needs. Unlike commercial brand-name drugs, compounded medications are not FDA-approved and do not undergo pre-market federal review for safety, effectiveness and manufacturing quality.
Reuters notes that Hims & Hers previously drew scrutiny from Novo Nordisk over its compounded semaglutide offerings. The telehealth company also faced mounting regulatory pressure after the FDA declared national GLP-1 shortages resolved, closing the loophole that previously allowed pharmacies to sell compounded versions of brand-name weight loss drugs.
Under the new deal, Hims & Hers has agreed not to sell compounded versions or knockoffs of Eli Lilly’s obesity medications. The arrangement gives Lilly tighter control over how its branded treatments are distributed while giving Hims & Hers access to FDA-approved therapies, though narrow patient-specific compounding remains legal under federal law.
Could the Eli Lilly and Hims & Hers deal make weight loss medications more affordable?
Matching LillyDirect’s starting cash prices gives self-pay consumers another pathway to brand-name treatment, particularly when commercial insurance plans exclude obesity drugs, cap coverage or impose strict prior authorization rules. Even so, out-of-pocket affordability remains a major barrier once recurring monthly membership fees and long-term maintenance costs are factored in.
Payment rules also vary across healthcare accounts. While the cost of the prescription medication itself can often be reimbursed through a Health Savings Account (HSA) or Flexible Spending Account (FSA), Hims & Hers’ monthly membership fees are not eligible for HSA or FSA funds.
Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital and associate professor of medicine and pediatrics at Harvard Medical School, noted, “This is a really complicated question, and the reason why it’s so complicated is that we do have this issue with access and insurance coverage and the proper prescribing of these medications.”
Her perspective underscores that meaningful access goes beyond online convenience—it requires comprehensive medical evaluation, sustained clinical follow-up and pricing structures patients can realistically afford over time.
What does the Eli Lilly partnership mean for the future of telehealth weight loss care?
The agreement reflects the deepening ties between major drugmakers and telehealth platforms as prescription weight management moves increasingly online. With both Eli Lilly and Novo Nordisk now offering FDA-approved obesity treatments through Hims & Hers, competition in virtual obesity care is set to intensify.
The arrival of an oral GLP-1 tablet like Foundayo could also reshape how patients approach weight loss treatment, offering an alternative for people who prefer a daily pill over weekly injections due to medical history, side-effect profiles or personal preference.
Still, streamlined checkout shouldn’t replace thorough medical oversight—or push patients toward a medication simply because it is heavily marketed online. While Eli Lilly and Hims & Hers have made it simpler for eligible patients to obtain Zepbound and Foundayo from home, ongoing membership dues and medication costs remain significant considerations that warrant a careful conversation with a trusted healthcare professional before starting treatment.
Bottom line
The Hims & Hers collaboration with Eli Lilly offers eligible individuals a streamlined way to obtain Zepbound and Foundayo through a digital consultation and prescription. Although the initial self-pay prices may make it more accessible to some, membership dues and medication costs remain significant obstacles. Before beginning treatment with either medication, patients should consult with a competent health care professional about treatment options.
Frequently Asked Questions
Does Hims & Hers accept insurance for weight loss medication?
No. Hims & Hers Weight Loss operates strictly on a self-pay model and does not accept health insurance. The $39 first-month and $149 monthly membership fees are not eligible for HSA or FSA reimbursement. However, the medication cost itself can generally be reimbursed using an HSA or FSA, depending on your plan administrator’s rules and eligibility requirements.
Are the weight-loss medications sold through Hims & Hers FDA-approved?
Yes, Zepbound and Foundayo are FDA-approved prescription medications, but patients must have a valid prescription from a licensed healthcare provider.
Citations
Erman M. Lilly to sell obesity drugs directly on Hims & Hers site. Reuters. November 6, 2026. Accessed November 13, 2026. https://www.reuters.com/legal/litigation/lilly-sell-obesity-drugs-directly-hims-hers-site-2026-11-06/
Eli Lilly. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines. Eli Lilly and Company. November 6, 2026. Accessed November 13, 2026. https://lilly.gcs-web.com/news-releases/news-release-details/lilly-and-hims-hers-expand-access-fda-approved-lilly-medicines
FDA. FDA Approves First New Molecular Entity Under National Priority Voucher Program. U.S. Food and Drug Administration. April 2026. Accessed November 13, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program
Jacobsen S, Fick M. Novo Nordisk sues Hims after $49 weight-loss pill sparks FDA backlash. Reuters. February 9, 2026. Accessed November 13, 2026. https://www.reuters.com/sustainability/boards-policy-regulation/novo-nordisk-shares-rise-hims-abandons-49-weight-loss-pill-2026-02-09/

